Law Office of Brodsky & Smith, LLC Announces
Investigation of Inspire Pharmaceuticals, Inc.
April 06, 2011 11:33 PM Eastern Daylight Time
BALA CYNWYD, Pa.--(EON: Enhanced Online News)--Law office of Brodsky & Smith, LLC announces that it
is investigating potential claims against the Board of Directors of Inspire Pharmaceuticals, Inc. (“Inspire” or the
“Company”) (Nasdaq - ISPH) relating to the proposed acquisition by Merck & Co. (“Merck”).
Under the terms of the transaction, Inspire shareholders would receive $5.00 in cash for each share of common
stock they own. The proposed transaction has an approximate value of $430 million. The investigation concerns
possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Inspire by not
acting in Inspire shareholders' best interests in connection with the sale process to Merck. The transaction may
undervalue Inspire as Inspire stock traded at $8.40 as recently as December 31, 2010 and an analyst placed a
$10.00 price target on the stock.
If you own shares of Inspire stock and wish to discuss the legal ramifications of the proposed transaction, or have
any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to
you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at
Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at
email@example.com, visiting http://brodsky-smith.com/274-isph-inspire-pharmaceuticals-inc.html,
or by calling toll free 877-LEGAL-90.
Brodsky & Smith, LLC
Jason L. Brodsky, Esquire
Evan J. Smith, Esquire